Skip to content
    OrbiMed logo

    OrbiMed

    New York, New York, United StatesFounded 1989
    www.orbimed.comLinkedIn
    HealthcareBiotech & Life Sciences

    OrbiMed is a global healthcare investment firm founded in 1989, headquartered in New York City. It invests across the healthcare industry from start-ups to large multinational corporations through private equity, venture capital, public equity, and royalty/credit funds, managing approximately $20 billion in assets.

    43% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $91.8M (across 489 rounds with reported amounts).

    Find people at OrbiMed on Goldilocks AI

    Portfolio

    343

    Fund Size

    $1.9B

    Top Stage

    Series B

    Last 12 Mo

    38

    Team

    CL

    Carl L. Gordon, Ph.D., CFA

    Managing Partner

    GC

    Geoffrey C. Hsu, CFA

    Managing Partner

    WC

    W. Carter Neild, CFA

    Managing Partner

    CS

    C. Scotland Stevens

    General Partner

    MR

    Matthew Rizzo

    General Partner

    DC

    Dina Chaya, Ph.D., CFA

    Partner

    DX

    Diyong Xu

    Partner

    EC

    Erez Chimovits

    Partner

    JG

    Joshua Golomb

    Partner

    MR

    Mark R. Jelley

    Partner

    ME

    Michael Eggenberg

    Partner

    SD

    Steven D. Wang, Ph.D., CFA

    Partner

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    560 investments
    CompanyRoundAmountDate
    Treeline Biosciences logoTreeline BiosciencesSeries A$200MSep 2026
    Braveheart Bio logoBraveheart BioUnknown$185MSep 2026
    Nucleus RadioPharma logoNucleus RadioPharmaSeries A$56MAug 2026
    NextCure logoNextCureSeries B$500MAug 2026
    Fore Biotherapeutics logoFore BiotherapeuticsUnknown$67.4MJul 2026
    AAccroSeries C$50MMay 2026
    Terns Pharmaceuticals logoTerns PharmaceuticalsSeries C$87MMay 2026
    VVivacta BiotechnologySeries A$50MApr 2026
    Vivacta logoVivactaSeries A$50MApr 2026
    Terremoto Biosciences logoTerremoto BiosciencesSeries C$108MApr 2026
    Adcendo ApS logoAdcendo ApSSeries C$75MApr 2026
    Sidewinder logoSidewinderSeries B$137MApr 2026
    SpectronRx logoSpectronRxSeries C$85MApr 2026
    Stairmed logoStairmedGrowth—Apr 2026
    Pinnacle Medicines logoPinnacle MedicinesSeries B$89MMar 2026
    Congruence Therapeutics logoCongruence TherapeuticsSeries B$39.5MMar 2026
    QQuantXSeries B$85MFeb 2026
    QuantX Biosciences logoQuantX BiosciencesSeries B$85MFeb 2026
    Mendra logoMendraSeries A$82MJan 2026
    Mirador logoMiradorSeries B$250MJan 2026
    Mirador Tx logoMirador TxSeries B$250MJan 2026
    Biobeat logoBiobeatSeries B$50MJan 2026
    Aviceda logoAvicedaSeries C—Jan 2026
    SSidewinder TherapeuticsSeries B$137MJan 2026
    Sidewinder logoSidewinderSeries B$137MJan 2026
    Page 1 of 23

    Top Co-Investors

    RA Capital Management85 shared
    Cormorant Asset Management48 shared
    Foresite Capital46 shared
    Logos Capital40 shared
    LAV38 shared
    Novo Capital35 shared
    Wellington Management34 shared
    HBM Healthcare Investments33 shared
    SR One33 shared
    The Invus Group, LLC33 shared
    Vivo Capital32 shared
    Alexandria Venture Investments30 shared
    Pontifax30 shared
    Surveyor Capital29 shared
    Sofinnova Partners29 shared
    Novo Holdings A/S29 shared
    Rock Springs Capital27 shared
    New Enterprise Associates26 shared
    Osage University Partners26 shared
    Samsara BioCapital26 shared

    Last updated: 7 October 2026